SLC6A9抗体—艾普蒂 新品

+ +

•  

   

     Western blot analysis of ATPB expression in HeLa cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

SLC6A9 antibody targets the solute carrier family 6 member 9 (SLC6A9), a protein encoded by the *SLC6A9* gene, also known as glycine transporter 1 (GlyT1). GlyT1 is a sodium- and chloride-dependent neurotransmitter transporter primarily expressed in glial cells and certain neurons, where it regulates glycine reuptake from synaptic clefts. This transporter plays a critical role in modulating glycine-mediated neurotransmission, particularly in regions like the brainstem, spinal cord, and retina. GlyT1 is essential for maintaining extracellular glycine homeostasis, influencing both inhibitory (via glycine receptors) and excitatory (via NMDA receptor co-activation) signaling pathways.

Antibodies against SLC6A9 are widely used in neuroscience research to study glycinergic system dynamics, glial cell function, and neurological disorders linked to glycine dysregulation, such as schizophrenia, neurodegenerative diseases, and chronic pain. These antibodies enable techniques like immunohistochemistry, Western blotting, and immunofluorescence to visualize GlyT1 expression patterns in tissues or cultured cells. Specificity validation (e.g., knockout controls) is crucial due to potential cross-reactivity with homologous transporters. Recent studies also explore GlyT1's role in tumor biology, as its expression is altered in some cancers. Researchers utilize SLC6A9 antibodies to investigate therapeutic strategies targeting GlyT1. including inhibitors aimed at enhancing NMDA receptor activity for cognitive disorders.